Answers are grounded in this paper and cite their sources.
Christos Kyratsous, Vice President of Research, Infectious Diseases, and Viral Vector Technologies at Regeneron Pharmaceuticals, and Alina Baum, Associate Director, Infectious Diseases Associate at Regeneron Pharmaceuticals, discuss the development of antibody therapeutics targeting the spike protein of SARS-CoV-2.
No takes yet. Share an insight, caveat, or question.
Baum et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: